Teriparatide (PTH 1-34) is a recombinant peptide consisting of the first 34 amino acids of the 84-amino acid human parathyroid hormone. Marketed as Forteo (Eli Lilly), it was the first anabolic bone-forming agent approved by the FDA (2002) for the treatment of osteoporosis with high fracture risk.

Overview

Parathyroid hormone is the primary regulator of calcium homeostasis, acting on bone and kidney to maintain serum calcium within a narrow physiological range. The critical insight underlying teriparatide therapy is that continuous PTH elevation (as in hyperparathyroidism) causes net bone resorption, while intermittent PTH exposure paradoxically stimulates net bone formation. This "anabolic window" is exploited by once-daily subcutaneous injection of PTH 1-34, which produces a transient spike in PTH1R activation followed by rapid clearance.

Teriparatide was a paradigm shift in osteoporosis treatment. Prior to its approval, all available therapies (bisphosphonates, estrogen, calcitonin, raloxifene) were antiresorptive — they slowed bone loss but could not rebuild lost bone architecture. Teriparatide actively stimulates new bone formation, increases trabecular connectivity, and improves bone microarchitecture in ways that antiresorptives cannot.

The N-terminal 1-34 fragment retains full biological activity at the PTH1R receptor. The remaining C-terminal residues (35-84) are not required for receptor binding or activation, though they may have independent biological effects through distinct receptors (see PTH 1-84).

Mechanism of Action

PTH1R Receptor Signaling

Teriparatide binds the PTH type 1 receptor (PTH1R), a class B G protein-coupled receptor expressed on osteoblasts, osteocytes, and renal tubular cells. Receptor activation triggers multiple downstream signaling cascades:

1. Gs/cAMP/PKA pathway: The primary signaling pathway. PTH1R couples to Gs, activating adenylyl cyclase and increasing intracellular cAMP. PKA activation phosphorylates CREB, driving transcription of osteoblast differentiation genes including Runx2 and osterix (Jilka, 2007).
2. Gq/PLC/PKC pathway: PTH1R also couples to Gq, activating phospholipase C and increasing intracellular calcium and PKC activity. This pathway contributes to osteoblast proliferation.
3. Beta-arrestin signaling: PTH1R engagement recruits beta-arrestins, which mediate receptor internalization and activate ERK1/2 through a G protein-independent mechanism.
4. Wnt pathway activation: Intermittent PTH suppresses sclerostin (SOST) and DKK1, key inhibitors of the Wnt/beta-catenin pathway. Wnt activation is a major mechanism for PTH's anabolic effect, promoting osteoblast differentiation and survival (Keller & Kneissel, 2005).

The Intermittent vs. Continuous Paradox

The distinction between intermittent and continuous PTH exposure is fundamental:

• Intermittent exposure (once-daily injection): Transiently activates osteoblasts, increases osteoblast number and activity, suppresses osteoblast apoptosis, and downregulates RANKL/OPG ratio favoring net formation. The brief cAMP spike preferentially activates pro-formation gene programs.
• Continuous exposure (hyperparathyroidism): Sustained cAMP elevation shifts the RANKL/OPG ratio toward resorption, activates osteoclastogenesis, and leads to net bone loss. Prolonged PKA activation upregulates different gene sets than transient activation.

This pharmacological paradox is dose- and time-dependent. The once-daily 20 mcg subcutaneous injection produces a plasma PTH spike lasting approximately 4-6 hours, followed by return to baseline — mimicking the "anabolic window" (Tam et al., 1982).

Osteoblast Biology

Teriparatide acts on osteoblast lineage cells at multiple stages:

• Osteoblast precursors: Stimulates proliferation and commitment to osteoblast differentiation.
• Mature osteoblasts: Increases activity and matrix production, extending osteoblast lifespan by suppressing apoptosis.
• Osteocytes: Reduces sclerostin production, amplifying Wnt signaling throughout the osteoblast network.
• Lining cells: Reactivates quiescent bone-lining cells (formerly active osteoblasts) back into matrix-producing osteoblasts — a unique mechanism not shared by other anabolic agents.

Reconstitution Calculator

Research

Safety Profile

Teriparatide has a well-characterized safety profile from extensive clinical use since 2002:

• Common adverse effects: Nausea (8%), headache (8%), dizziness (8%), leg cramps (3%), injection site reactions, transient hypercalcemia (11% mild, rarely clinically significant).
• Orthostatic hypotension: Can occur within 4 hours of initial doses. Patients should be seated during first injections.
• Hypercalcemia: Generally mild and transient. Serum calcium should be monitored. More common at 40 mcg than 20 mcg dose.

Black Box Warning: Osteosarcoma

Teriparatide carries a black box warning based on preclinical findings:

• In Fischer 344 rats treated with near-lifetime high-dose teriparatide, osteosarcoma incidence increased in a dose- and duration-dependent manner.
• This finding led to the initial 2-year treatment duration limit.
• However, the rat model is considered poorly predictive: rats have open growth plates throughout life and were exposed to doses 3-58 times the human dose for nearly their entire lifespan.
• Post-marketing surveillance over 15+ years and analysis of the Forteo Patient Registry have not identified an increased osteosarcoma risk in humans (Gilsenan et al., 2021).
• In 2020, the FDA removed the 2-year limitation on teriparatide use, though most clinicians still limit treatment to 2 years followed by antiresorptive consolidation.

Contraindications

• Unexplained elevated alkaline phosphatase
• Paget's disease of bone
• Prior external beam or implant radiation therapy to the skeleton
• Open epiphyses (children and young adults)
• Pre-existing hypercalcemia
• Bone metastases or history of skeletal malignancies

Pharmacokinetic Profile